Publication relative à des notifications de transparence

Nyxoah SA announced that it received a transparency notification on March 19, 2026, regarding Robert Taub and his related entity Robelga SRL crossing the 3% voting rights threshold on December 30, 2025. Robert Taub and his controlled entities now hold 4,360,800 voting rights (10.14% of total voting rights), comprising 4,310,800 voting rights attached to securities and 50,000 assimilated financial instruments.

03/20/2026, 5:30 PM • GlobeNewswire

Publication relating to transparency notifications

Nyxoah SA announced that it received a transparency notification on March 19, 2026, regarding Robert Taub and Robelga SRL crossing above the 3% threshold on December 30, 2025. The combined holding represents 10.14% of total voting rights (4,360,800 voting rights out of 43,026,460), consisting of 4,310,800 voting rights linked to securities and 50,000 equivalent financial instruments in the form of warrants.

03/20/2026, 5:30 PM • GlobeNewswire

Publication relating to transparency notification

Nyxoah SA announced that BNP Paribas Asset Management Europe SAS crossed below the 3% voting rights threshold on March 9, 2026, reducing its holding from 1,409,791 to 1,307,817 voting rights (3.00% of total voting rights). The notification was filed in accordance with Belgian transparency disclosure requirements.

03/13/2026, 5:30 PM • GlobeNewswire

Publication relative à une notification de transparence

Nyxoah SA announced that BNP Paribas Asset Management Europe SAS has crossed below the 3% voting rights threshold, reducing its holding from 1,409,719 to 1,307,817 voting rights (3.00% of total voting rights) as of March 9, 2026. The reduction was triggered by an acquisition or disposal of securities conferring voting rights.

03/13/2026, 5:30 PM • GlobeNewswire

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands

Nyxoah launched its Genio® system in the Netherlands, performing first successful implants at OLVG West and Zuyderland hospitals, offering an alternative treatment for Obstructive Sleep Apnea (OSA) patients who cannot tolerate CPAP.

12/17/2025, 1:05 AM • GlobeNewswire

Nyxoah Annonce le Lancement Commercial de la Thérapie Innovante Genio® Aux Pays-Bas

Nyxoah successfully launched its Genio® neurostimulation system for Obstructive Sleep Apnea treatment in the Netherlands, with first implantations at OLVG West and Zuyderland hospitals, offering patients an alternative to CPAP therapy.

12/17/2025, 1:05 AM • GlobeNewswire

Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule

Nyxoah announced CMS has increased Medicare reimbursement for its Genio hypoglossal nerve stimulation therapy by 48% for hospital outpatient departments and 58% for ambulatory surgery centers in 2026, which is expected to support broader therapy adoption.

11/26/2025, 1:45 AM • GlobeNewswire

La Thérapie Genio® de Nyxoah Bénéficie d'une Augmentation Significative du Remboursement Medicare en 2026 en Vertu de la Règle Finale du CMS

Nyxoah announced a substantial Medicare reimbursement increase for its Genio® sleep apnea treatment in 2026, with hospital outpatient services reimbursement rising 48% to $45,000 and ambulatory surgery center reimbursement increasing 58% to $42,373.

11/26/2025, 1:45 AM • GlobeNewswire

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio

Nyxoah secured $77 million in financing through a private placement, registered direct offering, and convertible bond to support U.S. commercialization of its Genio system for treating Obstructive Sleep Apnea (OSA).

11/13/2025, 7:30 PM • GlobeNewswire

Nyxoah Q2 Revenue Jumps 74 Percent

Nyxoah received FDA Pre-Market Approval for its GENEO system to treat obstructive sleep apnea, launching a 50-person commercial team targeting high-volume U.S. implanting centers with 73.8% year-over-year revenue growth.

08/18/2025, 5:21 PM • The Motley Fool

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025

Nyxoah received FDA approval for its Genio® system to treat moderate to severe obstructive sleep apnea, with Q2 2025 revenue expected to grow 73% to €1.3 million. The company is transferring R&D activities to the US and Belgium and is facing a patent lawsuit from Inspire Medical Systems.

08/11/2025, 1:00 AM • GlobeNewswire

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Nyxoah received FDA approval for its Genio® system to treat moderate to severe Obstructive Sleep Apnea, reporting Q2 2025 revenue of €1.3 million and facing a patent infringement lawsuit from Inspire Medical Systems.

08/11/2025, 1:00 AM • GlobeNewswire

Information on the total number of voting rights and shares

Nyxoah SA disclosed its current share capital and voting rights information, reporting 37,435,640 total securities and 2,822,816 potential subscription rights, and announced an upcoming extraordinary shareholders' meeting on July 2, 2025.

06/27/2025, 4:30 PM • GlobeNewswire